Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea

This study has been completed.
Sponsor:
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT00483145
First received: June 4, 2007
Last updated: June 2, 2008
Last verified: June 2008
  Purpose

To evaluate efficacy and adverse effect from long-pulsed dye laser versus long-pulsed dye laser-mediated photodynamic therapy for acne vulgaris and rosacea.


Condition Intervention
Acne Vulgaris and Rosacea
Device: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)
Device: Long-pulsed dye laser
Device: Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind
Official Title: Laser-Mediated Photodynamic Therapy of Acne Vulgaris and Rosacea

Resource links provided by NLM:


Further study details as provided by Bispebjerg Hospital:

Study Start Date: November 2006
Study Completion Date: November 2007
Arms Assigned Interventions
Active Comparator: 1
Long-pulsed dye laser (Candela)
Device: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate) Device: Long-pulsed dye laser
Active Comparator: 2
Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
Device: Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate) Device: Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Inflammatory acne and rosacea
  • Skin types I-IV

Exclusion Criteria:

  • Patients younger than 18 years
  • Skin types V and VI
  • Topical and systemic conventional acne treatments
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00483145

Locations
Denmark
Bispebjerg Hospital
Copenhagen NV, Denmark, 2400
Sponsors and Collaborators
Bispebjerg Hospital
Investigators
Principal Investigator: Merete Hædersdal Bispebjerg Hospital
  More Information

No publications provided

Responsible Party: Merete Hædersdal, Bispebjerg Hospital
ClinicalTrials.gov Identifier: NCT00483145     History of Changes
Other Study ID Numbers: KF-01-328309
Study First Received: June 4, 2007
Last Updated: June 2, 2008
Health Authority: Denmark: The Ministry of the Interior and Health

Additional relevant MeSH terms:
Acne Vulgaris
Rosacea
Acneiform Eruptions
Skin Diseases
Facial Dermatoses
Sebaceous Gland Diseases
Methyl 5-aminolevulinate
Aminolevulinic Acid
Photosensitizing Agents
Dermatologic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on August 01, 2014